CY1112805T1 - Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης - Google Patents

Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης

Info

Publication number
CY1112805T1
CY1112805T1 CY20121100403T CY121100403T CY1112805T1 CY 1112805 T1 CY1112805 T1 CY 1112805T1 CY 20121100403 T CY20121100403 T CY 20121100403T CY 121100403 T CY121100403 T CY 121100403T CY 1112805 T1 CY1112805 T1 CY 1112805T1
Authority
CY
Cyprus
Prior art keywords
type
pde
inhibitors
diseases
phosphodiesterase
Prior art date
Application number
CY20121100403T
Other languages
Greek (el)
English (en)
Inventor
Sonali Rudra
Nidhi Gupta
Lalit Kumar Baregama
Ritu Agarwal
Vinayak Vasantrao Khairnar
Mandadapu Raghu Ramaiah
Venkata P Palle
Sarala Balachandran
Atul Kondaskar
Manohar Salla
Abhijit Ray
Sunanda G Dastidar
Lalitha Vijaykrishnan
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of CY1112805T1 publication Critical patent/CY1112805T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20121100403T 2007-03-14 2012-04-26 Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης CY1112805T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN550DE2007 2007-03-14
EP08737621A EP2124944B1 (en) 2007-03-14 2008-03-14 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
CY1112805T1 true CY1112805T1 (el) 2016-02-10

Family

ID=39575541

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100403T CY1112805T1 (el) 2007-03-14 2012-04-26 Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης

Country Status (21)

Country Link
US (1) US8420666B2 (enExample)
EP (1) EP2124944B1 (enExample)
JP (1) JP5671236B2 (enExample)
KR (1) KR101568884B1 (enExample)
CN (2) CN101801376A (enExample)
AP (1) AP2453A (enExample)
AT (1) ATE545417T1 (enExample)
AU (1) AU2008224541B2 (enExample)
CA (1) CA2680625C (enExample)
CY (1) CY1112805T1 (enExample)
DK (1) DK2124944T3 (enExample)
EA (1) EA018670B9 (enExample)
ES (1) ES2382715T3 (enExample)
HR (1) HRP20120361T1 (enExample)
MX (1) MX2009009793A (enExample)
NZ (1) NZ579645A (enExample)
PL (1) PL2124944T3 (enExample)
PT (1) PT2124944E (enExample)
SI (1) SI2124944T1 (enExample)
WO (1) WO2008111010A1 (enExample)
ZA (1) ZA200906418B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1934219A1 (en) * 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
RU2008139599A (ru) * 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
PL2057125T3 (pl) * 2006-08-16 2011-09-30 Hoffmann La Roche Nienukleozydowe inhibitory odwrotnej transkryptazy
CA2735956A1 (en) * 2008-09-19 2010-04-29 Ranbaxy Laboratories Limited Phosphodiestarase inhibitors
EP2848256B1 (en) 2009-12-08 2018-11-14 Vanderbilt University Improved methods and compositions for vein harvest and autografting
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EA037544B1 (ru) * 2017-04-04 2021-04-12 Х. Лундбекк А/С ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
CN111465410B (zh) 2017-12-14 2022-10-25 H.隆德贝克有限公司 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN113200997B (zh) * 2021-05-07 2023-10-03 上海合全医药有限公司 2,5-二氧杂-8-氮杂螺[3.5]壬烷及其盐的合成方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047518A (en) 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
NL128816C (enExample) 1965-04-22
GB1159490A (en) 1966-02-09 1969-07-23 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3639434A (en) 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
US3780177A (en) * 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
CH513845A (de) * 1967-11-17 1971-10-15 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
GB1253831A (en) 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US3700681A (en) * 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3947478A (en) * 1972-01-12 1976-03-30 Akzona Incorporated Alkylated 3,20-diketo-Δ4 -steroids of the pregnane series
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (enExample) * 1972-05-19 1975-08-18 Bofors Ab
SE378110B (enExample) 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US4098804A (en) 1973-05-30 1978-07-04 Jouveinal S.A. Esters of 21-thiol prednisone and prednisolone
FR2231374B1 (enExample) * 1973-05-30 1976-10-22 Jouveinal Sa
US4011258A (en) 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
ZA744259B (en) * 1973-08-17 1975-06-25 American Cyanamid Co Topical steroid
US3980778A (en) 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
NL7502252A (nl) * 1974-02-27 1975-08-29 Pierrel Spa Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden.
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4076708A (en) 1976-12-22 1978-02-28 Schering Corporation Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby
US4124707A (en) 1976-12-22 1978-11-07 Schering Corporation 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor
US4081541A (en) 1976-12-28 1978-03-28 Rorer Italiana S.P.A. Steroid derivatives
DE2735110A1 (de) 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
JPS6040439B2 (ja) 1978-03-29 1985-09-11 大正製薬株式会社 ヒドロコルチゾン誘導体
CA1201114A (en) 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
CY1273A (en) 1980-07-09 1985-03-08 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates
US4298604B1 (en) * 1980-10-06 1998-12-22 Schering Corp Clotrimazole-betamethasone dipropionate combination
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3133081A1 (de) 1981-08-18 1983-03-10 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung
US4472392A (en) 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8425104D0 (en) * 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
CA1326662C (en) 1988-03-09 1994-02-01 Yutaka Mizushima 11.beta.,17.,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(e,e)-3,7,11-trimethyl-2,6,10-dodecatrienoate]
US5278156A (en) 1988-03-09 1994-01-11 Kuraray Co., Ltd. 11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7, 11-trimethyl-2,6,10-dodecatrienoate]
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
PL165803B1 (pl) 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
EP0542355A1 (en) 1991-11-15 1993-05-19 Merck Frosst Canada Inc. Amorphous (Quinolin-2-ylmethoxy)indoles as leukotriene antagonists
US5254541A (en) 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indole/cyclodextrin complex
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
TW438585B (en) 1995-02-06 2001-06-07 Astra Ab Pharmaceutical compositions for topical administration for prophylaxis and/or treatment of herpesvirus infections
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
HUP9903009A3 (en) 1996-06-25 2002-01-28 Pfizer Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
NZ334213A (en) 1996-09-04 2000-08-25 Pfizer Indazole derivatives as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) for treating asthma, arthritis, bronchitis, CNS disorders
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
IL135105A0 (en) * 1997-10-06 2001-05-20 American Cyanamid Co The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
NZ503995A (en) 1997-11-04 2003-02-28 Pfizer Prod Inc Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors
SK6252000A3 (en) 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
JP2000198734A (ja) 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
ES2197092T3 (es) 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
US20030176421A1 (en) * 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1345935A2 (en) 2000-12-21 2003-09-24 Warner-Lambert Company LLC Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
WO2002051837A2 (en) 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
HUP0400682A2 (hu) 2000-12-22 2004-06-28 Wyeth 5-Hidroxitriptamin-6-ligandumként használható heterociklilalkilindol- és -azaindol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA02002749A (es) 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
TW200406385A (en) * 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
CA2518398A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
AU2004259738B2 (en) 2003-07-17 2011-11-17 Plexxikon, Inc. PPAR active compounds
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
US7396833B2 (en) 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
CA2567977A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
ATE415400T1 (de) 2004-07-05 2008-12-15 Astellas Pharma Inc Pyrazolopyridinderivate
WO2006016237A2 (en) 2004-08-04 2006-02-16 Ranbaxy Laboratories Limited Heterocyclic derivatives as anti-inflammatory agents
WO2006021848A1 (en) 2004-08-27 2006-03-02 Ranbaxy Laboratories Limited Anti-inflammatory agents
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NZ555566A (en) 2004-11-22 2009-12-24 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20090131430A1 (en) 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
JP2008521829A (ja) 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
AU2005311826A1 (en) 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
US20090036472A1 (en) 2005-02-02 2009-02-05 Palle Venkata P Azabicyclo derivatives as anti-inflammatory agents
MX2007010721A (es) 2005-03-01 2007-11-13 Pfizer Ltd Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico.
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
US20100022571A1 (en) * 2005-09-16 2010-01-28 Palle Venkata P Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
EP1940836A1 (en) * 2005-09-29 2008-07-09 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
US20120004201A1 (en) * 2008-09-19 2012-01-05 Sonali Rudra Phosphodiestarase inhibitors

Also Published As

Publication number Publication date
WO2008111010A1 (en) 2008-09-18
EP2124944B1 (en) 2012-02-15
JP2010521451A (ja) 2010-06-24
EP2124944A1 (en) 2009-12-02
CA2680625A1 (en) 2008-09-18
ATE545417T1 (de) 2012-03-15
PL2124944T3 (pl) 2012-08-31
AP2009004977A0 (en) 2009-10-31
US20100292196A1 (en) 2010-11-18
EA018670B9 (ru) 2014-01-30
CN101801376A (zh) 2010-08-11
EA200970852A1 (ru) 2010-04-30
JP5671236B2 (ja) 2015-02-18
AP2453A (en) 2012-08-31
DK2124944T3 (da) 2012-04-23
ES2382715T3 (es) 2012-06-12
ZA200906418B (en) 2010-05-26
KR20090120505A (ko) 2009-11-24
SI2124944T1 (sl) 2012-05-31
AU2008224541B2 (en) 2013-08-22
KR101568884B1 (ko) 2015-11-12
CN103497185A (zh) 2014-01-08
EA018670B1 (ru) 2013-09-30
US8420666B2 (en) 2013-04-16
CA2680625C (en) 2016-02-23
HRP20120361T1 (hr) 2012-05-31
PT2124944E (pt) 2012-05-17
NZ579645A (en) 2012-01-12
AU2008224541A1 (en) 2008-09-18
HK1138758A1 (en) 2010-09-03
MX2009009793A (es) 2009-10-16

Similar Documents

Publication Publication Date Title
CY1112805T1 (el) Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης
SG155909A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
EA201290515A1 (ru) Аминопиримидины в качестве syk ингибиторов
PH12016500791A1 (en) Novel amino pyrimidine derivatives
JO3108B1 (ar) بيرروليدينونات أروماتية مخلطة مندمجة كمثبطات syk
IN2015DN02008A (enExample)
ECSP088813A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
EA201890827A1 (ru) Конденсированные производные пиразола в качестве ингибиторов киназы
ATE517868T1 (de) Pyrazinverbindungen, ihre verwendung und herstellungsverfahren
EA201301183A1 (ru) Гетероциклические соединения в качестве ингибиторов киназ
EA201892436A1 (ru) Пиримидиновые соединения в качестве ингибиторов jak киназы
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
MX2020006587A (es) Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
WO2007100610A3 (en) Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
WO2007124181A3 (en) Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
MX2009003100A (es) Inhibidores de fosfodiesterasa tipo iv.
WO2009115874A3 (en) Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
MX2010008750A (es) Nuevos macrolidos y su uso.
WO2009102997A3 (en) Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase
NO20070820L (no) Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
MX385381B (es) Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).